Delving into the Latest Updates on Hydroxocobalamin with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

HXC, Hydroxocobalamin (JAN/USP/INN), Hydroxocobalamin anhydrous

+ [14]

Target

IFNAR

Action

agonists

Mechanism

IFNAR agonists(Interferon alpha/beta receptor agonists)

Therapeutic Areas

Nervous System DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [3]

Active Indication

Cyanide poisoningAmblyopiaOptic Atrophy, Hereditary, Leber+ [6]

Inactive Indication-

Originator Organization

Merck & Co., Inc.

Active Organization

SERB SA

China Resources Double-Crane Pharmaceutical Co., Ltd.

Anyang Jiuzhou Pharmaceutical Co. Ltd.

+ [5]

Inactive Organization

Merck & Co., Inc.

Drug Highest PhaseApproved

First Approval Date

United States (18 Apr 1975),

Poisoning

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC62H89CoN13O15P

InChIKeyXVXCLEXSDVMESA-UHFFFAOYSA-L

CAS Registry13422-51-0

This is a 4-week pilot, multicenter, randomized, double-blinded placebo controlled trial of hydroxocobalamin and butyrate in ulcerative colitis (UC) that will occur in two phases. The main objectives of this study are to determine the capacity of hydroxocobalamin and butyrate to reduce calprotectin in those with inflammatory disease in UC to determine the safety and preferential dose of hydroxocobalamin with butyrate in UC.

Start Date01 Jan 2024

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

NCT05536596

/ Not yet recruitingPhase 2/3IIT

Pharmacological Treatment on the Recovery of Neurosensory Disturbance After Bilateral Sagittal Split Osteotomy: a Randomized, Double-blind Trial

The bilateral sagittal split osteotomy (BSSO) of the mandible is one of the most used surgical techniques to achieve a harmonious jaw relation in the context of orthognathic surgery. Nevertheless, one of its main complications is neurosensory damage to the inferior alveolar nerve, which can cause severe impact in the quality of life on patients who suffer from it permanently. The purpose of this randomized clinical trial is to provide rigorous scientific evidence of the pharmacological effect of 1) Melatonin, 2) combination uridine triphosphate (UTP), cytidine monophosphate (CMP), and hydroxycobalamin (UTP/CMP/hydroxycobalamin) and 3) hydroxycobalamin regarding neurosensory disturbances incidence and persistence after BSSO.

Start Date30 Sep 2022

Sponsor / Collaborator

Universitat Internacional de Catalunya

[+1]

IRCT20211207053311N1

/ RecruitingPhase 3IIT

Evaluation of response rate to hydroxycobalamin treatment in patients with methylmalonic acidemia

Start Date04 Feb 2022

Sponsor / Collaborator

Mashhad University of Medical Sciences

100 Clinical Results associated with Hydroxocobalamin

Login to view more data

100 Translational Medicine associated with Hydroxocobalamin

Login to view more data

100 Patents (Medical) associated with Hydroxocobalamin

Login to view more data

1,953

Literatures (Medical) associated with Hydroxocobalamin

04 Mar 2025·New Zealand Veterinary Journal

Effect of a pre-calving injectable trace mineral supplement on white blood cell function in seasonally calving pastoral dairy cows

Article

Author: Bates, AJ ; Laven, RA ; Fitzpatrick, C ; Wells, M

AIMSTo investigate the effect of injection of trace mineral supplement (TMS) 14-28 days before calving on white blood cell count (WBCC) and function, serum antioxidant capacity (SAC) and reactive oxygen species (ROS) in pasture-fed cattle after calving.METHODSOn each of two South Island, seasonally calving, pastoral dairy farms,1 month before dry-off, a random sample of 150 multiparous cows predicted to calve within 7 days of the herd's planned start of calving (PSC) were stratified on individual somatic cell count, age, breed and expected calving date. On each farm, 14-24 days before PSC, 60 selected cows were randomly assigned for TMS (Zn, Mn, Se, Cu) injection, and 60 were controls. All 240 cows were contemporaneously injected with hydroxocobalamin, and controls with Se. Blood samples were collected pre-injection and 3, 12 and 40 days after calving. Phagocytic activity, count and proportion of neutrophils, lymphocytes and monocytes, WBCC, ROS, SAC were measured. Plasma concentrations of Se, Cu and glutathione peroxidase (GPx) were monitored from a random subset of animals. Differences attributable to TMS were estimated using mixed-multivariable Bayesian analysis, expressed as mean and highest density interval (HDI).RESULTSThree and 40 days after calving, TMS-treated cows had 0.36 (90% HDI = 0.00-0.77) x 10⁹ and 0.25 (90% HDI = 0.00-0.55) x 10⁹ fewer neutrophils/L. Neutrophils comprised 6 (90% HDI = 0-11)% and 4 (90% HDI = 0-8)% less of the WBCC, and the neutrophil count was 14 (90% HDI = 0-27)% and 9 (90% HDI = 0-18)% less than controls. However, 3 days after calving, there were 7 (95% HDI = 2-12)% more cells phagocytosing and 2,900 (95% HDI = 2,600-3,200) more bacteria ingested/cell. Twelve and 40 days after calving, TMS-treated cows had 0.65 (95% HDI = 0.17-1.17) x 10⁹ and 0.28 (95% HDI = 0.00-0.59) x 10⁹ more lymphocytes/L. Lymphocytes comprised 10 (95% HDI = 3-18)% and 5 (95% HDI = 0-9)% more of the WBCC, and the lymphocyte count was 30 (95% HDI = 11-51)% and 9 (95% HDI = 0-9)% more than controls. There were no meaningful differences in ROS, SAC, ROS/SAC, other white blood cells, or WBCC. Plasma Cu, Se and GPx concentrations were above recommended thresholds.CONCLUSIONSPre-calving TMS injection was associated with differences in white blood cell population and function that may reduce the risk of disease.ABBREVIATIONSBHOB: Beta-hydroxybutyrate; GPx: Glutathione peroxidase; HDI: Highest density interval; MESF: Molecules of equivalent soluble fluorophore; OSi: Oxidative stress index; PSC: Planned start of calving; ROPE: Region of probable equivalence; ROS: Reactive oxygen species; SAC: Serum antioxidant capacity; THI: Temperature humidity index; TMS: Trace mineral supplement; WAIC: Widely applicable information criterion; WBCC: White blood cell count.

01 Feb 2025·Archivos Argentinos de Pediatria

Acute cyanide intoxication due to apricot seed ingestion

Article

Author: Güngör, Emre ; Orhan, Özhan ; Talay, Mehmet N

Introduction: Cyanide poisoning, whether it be accidental or intentional, remains a significant danger to adults and children, especially in societies where agriculture is a primary source of income. We examined the clinical follow-up, complications, and results of cyanide poisoning cases that occurred after eating the pits and seeds of plants containing cyanide glycosides, such as apricot kernels and almonds. Methods: Between 01/01/2017 and 01/08/2022, 14 children aged 1-18 years who were followed up with a prediagnosis of cyanide poisoning in our Paediatric Intensive Care Unit (PICU) were retrospectively analysed. Results: Eight of the patients followed with a preliminary diagnosis of cyanide poisoning were female and six were male. The most common admission month was July (42.8%) coinciding with the agricultural season. The most common symptoms at presentation were weakness and fatigue (n = 7). In the PICU, 4 patients presented lip cyanosis; 3, altered level of consciousness. Vomiting, seizure, headache, dizziness and palpitatons were less frequent. Four patients were treated with hydroxocobalamin (Cyanokit®) as an antidote due to acidosis in their blood gases. All patients treated for cyanide poisoning were discharged. Conclusions: Cyanide poisoning should be considered in paediatric patients with suspicious findings, sudden loss of consciousness, increased anion gap acidosis and lactic acidosis. The history of eating the seeds of plants such as apricot and almonds should be investigated.

27 Jan 2025·Cureus

Vasoplegic Syndrome Following Bypass: A Comprehensive Review of Pathophysiology and Proposed Treatments

Review

Author: Sanchez, Ana F ; Torrez, Jaime P ; Otsuki, Denise A ; Zeferino, Suely P ; Auler, José Otávio C

Following cardiopulmonary bypass (CPB) surgery, patients may experience vasoplegic or vasogenic shock syndrome. This condition has a variable incidence, reaching up to 44% in high-risk patients, with mortality rates ranging from 30% to 50%, primarily due to multiple organ failure. This complex condition is characterized by low arterial pressure, unresponsive vascular collapse to high doses of vasopressors, and biochemical signals of cellular oxygen debt. The cardiac output can either be low or abnormally elevated. A fundamental aspect of the pathophysiology of vasogenic syndrome after CPB is related to the dysfunction of vascular smooth muscle cell contraction. This syndrome is often associated with complex cardiac surgery such as reoperations, long periods of bypass and aorta clamping, and excessive blood transfusion. Some potential triggers that might lead to this condition include the preoperative use of antagonists of the renin-angiotensin system, calcium blockers antagonists, and chronic renal disease. Recent literature has advocated treating vasoplegic syndrome after bypass using oxide nitric synthase inhibitors, such as methylene blue and hydroxocobalamin, along with the progressive escalation of potent vasopressors and intravascular volume adjustment.

100 Deals associated with Hydroxocobalamin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01027	Hydroxocobalamin	V03AB33 B03BA03	DB00200

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cyanide poisoning	United States	BTG International, Inc.	15 Dec 2006
Amblyopia	Australia	Pfizer Australia Pty Ltd.	26 Jun 2006
Optic Atrophy, Hereditary, Leber	Australia	Pfizer Australia Pty Ltd.	26 Jun 2006
Anemia, Megaloblastic	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1996
Anemia, Megaloblastic	China	Anyang Jiuzhou Pharmaceutical Co. Ltd.	01 Jan 1996
Anemia, Pernicious	China	Anyang Jiuzhou Pharmaceutical Co. Ltd.	01 Jan 1996
Anemia, Pernicious	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1996
Neuralgia	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1996
Neuralgia	China	Anyang Jiuzhou Pharmaceutical Co. Ltd.	01 Jan 1996
Vitamin B 12 Deficiency	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1996
Vitamin B 12 Deficiency	China	Anyang Jiuzhou Pharmaceutical Co. Ltd.	01 Jan 1996
Poisoning	United States	Actavis	16 Aug 1978

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Methylmalonic Acidemia	Preclinical	United States	National Institutes of Health	09 Oct 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04054999 (CTgov)	Phase 4	Vasoplegia \| Liver transplant rejection	19	Hydroxocobalamin (Cyanokit)	vxhkopydbx(qqsrbznzni) = hncbroanzz twniajpgls (hnpzmfzfyn, hdaonqncne - gvnschyixe) View more	-	24 Jun 2024
				Methylene Blue (Methylene Blue)	vxhkopydbx(qqsrbznzni) = qwqztdprvp twniajpgls (hnpzmfzfyn, wzygvdhwxe - ycsdpegmhh) View more
ATS2023	Not Applicable	Shock	-	Hydroxycobalamin	(huvxwoalmb) = tejnivubbs uaaeioynwg (szbfckahyz ) View more	-	21 May 2023
				Vasopressors (norepinephrine, vasopressin, epinephrine)	(huvxwoalmb) = aceueecxsy uaaeioynwg (szbfckahyz ) View more
NCT03735316 (CTgov)	Phase 2	Vasoplegia \| Hypotension	8	Cardiopulmonary Bypass+Hydroxocobalamin (B12a)	mqwwwrlczy(fmlzwuzaed) = lypzcsvrhs hrhqormmyh (doyliqxglf, mjrkzffcul - kcroyhslhq) View more	-	10 May 2023
				Cardiopulmonary Bypass (Placebo)	mqwwwrlczy(fmlzwuzaed) = dickreqmhq hrhqormmyh (doyliqxglf, rpcxnfkbdl - iedbxmhuhe) View more
SSIEM2022	Not Applicable	Transcobalamin II Deficiency vitamin B12 \| folic acid \| homocysteine ... View more	-	Parenteral hydroxocobalamin	xyinigzzhe(petaspyvkg) = vuyodkhkmp wzplmulyhi (hnwuesvjwv ) View more	-	30 Aug 2022
ATS2021	Not Applicable	Vasoplegia	-	Hydroxocobalamin	(hqbkantiwl) = zgazmwayvi rxjuavbzke (jrmnkhxumx )	-	03 May 2021
START Program (ASH2007)	Not Applicable	Blast Phase Chronic Granulocytic Leukemia	157	Dasatinib 70 mg BID	jpuroksehh(hyibfvnpjn) = Cytopenias were noted for the majority of patients, and were manageable; grade 3-4 febrile neutropenia was recorded in 8% of patients wvefekjyhs (lgmzwszqqb ) View more	-	16 Nov 2007
				Cbi